Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSihuan Pharm
Stock Code00460
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是一家領先的醫藥公司,主要從事心腦血管藥物、抗感染藥物及其他藥物的生產與銷售,並擁有覆蓋全國31個省市及自治區近10,000家醫院的分銷網絡。
Listing Date2010-10-28
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港灣仔港灣道1號會展廣場辦公大樓4905室
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitesihuanpharm.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 4.60 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 0.01 / shares
Offer Period2010-10-20 to 2010-10-20
Global Offering Shares1,250,000,000 shares
HK Public Offer Shares (Initial)125,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)1,125,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO5,000,000,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share27.8%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 5,750,000,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 9.29B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣313.7百萬元
Period-End Cash Balance人民幣612.9百萬元
Listing Expenses~HK$ 229,000,000
Listing Expenses / Funds Raised~3.98%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2007200820092010-06
Revenue 286,349510,048708,907473,437
Cost of sales -60,526-133,551-191,915-127,074
Gross profit 225,823376,497516,992346,363
Other income and gains, net 22,744-8,014-16,34819,444
Selling and distribution expenses -22,732-38,906-48,810-26,364
Administrative expenses -38,856-53,405-78,809-52,420
Operating profit 186,979276,172373,025287,023
Net finance costs -2,5274705,6443,072
Share of associates and JVs 010,4272,3570
Profit before tax 184,452287,069381,026290,095
Income tax expense -5,626-53,621-67,370-42,683
Profit for the year 178,826233,448313,656247,412
Profit attributable to owners 179,266237,059326,316254,849
Balance Sheet
Item 2007200820092010-06
Cash and cash equivalents 262,380331,178612,859620,378
Trade and bills receivables 24,71471,424141,132310,519
Inventories 22,95339,39542,96749,298
Total current assets 310,047441,997796,958980,195
Total assets 630,546862,0511,173,4421,363,355
Total current liabilities 95,519127,194219,260179,924
Total liabilities 105,733146,191249,255190,685
Total equity 524,813715,860924,1871,172,670
Equity attributable to owners 524,813701,216907,5031,162,352
Interest-bearing borrowings 12,000000
Cash Flow Statement
Item 2007200820092010-06
Net cash from operating activities 182,565256,819385,648183,984
Net cash from investing activities -155,731-115,36516,062-2,526
Net cash from financing activities 193,758-72,656-120,029-173,939
Net increase in cash 220,59268,798281,6817,519
Purchase of PP&E -30,839-29,452-56,677-18,580
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 5.77
First Day OpenHK$ 6.05
First Day Change25.43%
First Day Volume804820000.0
First Day Turnover4724570000.0
Use of Proceeds
1、約20%或1101.0百萬港元,將用于研發: a.約10%或550.5百萬港元,將用于撥付我們的產品開 發及研究; b.約10%或550.5百萬港元,將用于開發我們現有的候 選產品 2、約15%或825.7百萬港元,將用于收購能補充及擴展我們現有產品組合的特定產品或生產線; 3、約15%或825.7百萬港元,將用于向建設位于廊坊及北京的兩項新生產設施所需的資本開支提供資金; 4、約30%或1651.4百萬港元,將用于我們發現適當的目標公司或業務進行上述活動時可能產生的并購機會; 5、約10%或550.5百萬港元,將用于加大銷售及分銷力度; 6、約10%或550.5百萬港元,將用作營運資金及一般公司開支。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466
Joint Bookrunners (2)
Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466
Joint Lead Managers (3)
Morgan Stanley Asia Limited CE AAD291 UBS Securities Hong Kong Limited CE BIN466 Daiwa Capital Markets Hong Kong Limited CE AAB639

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Gaoling Fund, L.P. 378,718,000 HKD — 6.60% — 6 months 2011-04-28
2 Quantum Partners LP 336,637,200 HKD — 5.90% — 6 months 2011-04-28
3 惠理基金管理香港有限公司 168,318,600 HKD — 2.90% — 6 months 2011-04-28
4 建银国际资产管理有限公司 126,237,800 HKD — 2.20% — 6 months 2011-04-28
5 云峰基金 168,318,600 HKD — 2.90% — 6 months 2011-04-28
6 中国人寿保险(海外)股份有限公司 168,318,600 HKD — 2.90% — 6 months 2011-04-28
7 中国人寿保险(集团)公司 252,480,200 HKD — 4.40% — 6 months 2011-04-28

Directors & Management

PositionChinese nameEnglish Name
Chairman車馮升—
Company Secretary陳燕玲,李健威—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東為Plenty Gold及車醫生。緊隨全球發售後(不計超額配股權),Plenty Gold持有約65.8%權益,車醫生持有約67.0%權益(包括其於Plenty Gold的51%實益權益及直接持股)。
About this page

This page shows Sihuan Pharm (00460) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect